-+ 0.00%
-+ 0.00%
-+ 0.00%

Zai Lab, Boehringer Ingelheim team up on DLL3 combo trial in lung cancer

PUBT·04/15/2026 12:43:27
Listen to the news
Zai Lab, Boehringer Ingelheim team up on DLL3 combo trial in lung cancer
  • Zai Lab entered clinical collaboration with Boehringer Ingelheim to test dual DLL3-targeting combination in small cell lung cancer.
  • Phase Ib/II study will evaluate obrixtamig, Boehringer DLL3/CD3 T-cell engager, with Zai Lab DLL3 antibody-drug conjugate zocilurtatug pelitecan.
  • Trial will enroll patients with extensive-stage small cell lung cancer plus poorly differentiated neuroendocrine carcinomas.
  • Zai Lab will supply zocilurtatug pelitecan, while Boehringer will sponsor trial, oversee day-to-day clinical operations.
  • Each company will retain rights to its respective assets under agreement.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zai Lab Ltd. published the original content used to generate this news brief on April 15, 2026, and is solely responsible for the information contained therein.